All adenocarcinoma articles
-
NewsCHMP recommends first broad RAS-targeted therapy for metastatic pancreatic cancer
The EMA’s human medicines committee’s positive opinion is based on data showing the oral therapy reduced the risk of death by more than fifty percent compared to chemotherapy.
-
NewsRadioligand therapy could address multiple cancer types
The investigational dual-targeting treatment provided strong and durable delivery to tumours, allowing for a high dose of targeted radiation, early results show.
-
NewsGilead reveals positive data for potential first-line adenocarcinoma treatment
The only Fc-silent anti- T-cell immunoreceptor with Ig and ITIM domains (TIGIT) antibody in Phase III for upper GI adenocarcinomas could be the first to market for these cancers.